drugset / Trial / NCT05197842

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

NCT05197842

Phase 1/2 Completed 93 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.

Timeline

Start
2022-02-22
Primary completion
2025-03-19
Completion
2025-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified Oral
Subject Resiquimod Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous